Poxel Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest, by Kuhn Thomas, was filed 02 Feb 2024.
Poxel: what insiders have been doing
Every trade that managers of Poxel disclose to AMF is tracked on this page. The company sits in the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for Poxel. The previous disclosure was published on 2 February 2024.
Looking back to 2022, when coverage begins, insiders filed 3 purchases and no sales.
Other companies in the same sector with recent insider buying flagged by our signals: Vivos Inc and Anixa Biosciences Inc. Every figure here comes from the filings published by AMF and describes the past, not future prices; it is not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
- 80,000 shares0ActionEuronext ParisISIN FR00124325162024DD948921Canonical exit: 28 Apr 2024 (T+90)
- 150,000 shares0ActionEuronext ParisISIN FR00124325162023DD894028
- 80,000 shares0ActionEuronext ParisISIN FR00124325162023DD882619Canonical exit: 27 Apr 2023 (T+90)
- 400,000 shares0ActionHors plateforme de négociationISIN FR00124325162022DD877946
- 150,000 shares0ActionHors plateforme de négociationISIN FR00124325162022DD858234
- 6,666 shares0ActionEuronext ParisISIN FR00124325162022DD819175Canonical exit: 27 Apr 2022 (T+90)
6 of 6 declarations
About Poxel
Poxel is a French biopharmaceutical company listed on Euronext Paris under ISIN FR0012432516. Headquartered in Lyon, France, with subsidiaries in Boston and Tokyo, the company focuses on the development of innovative treatments for serious chronic diseases driven by metabolic pathophysiology, notably type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH), and selected rare metabolic disorders. Founded in 2009 as a spin-off from Merck Serono, Poxel inherited a scientific heritage in metabolic disease research and has pursued a strategy centered on first-in-class and differentiated therapeutic candidates. The company was admitted to trading on Euronext Paris in February 2015, a milestone that broadened its investor base and strengthened its visibility in the European healthcare sector.
Poxel’s most important commercial asset is imeglimin, marketed in Japan under the TWYMEEG® brand in partnership with Sumitomo Pharma. This product has become a meaningful revenue generator for the company through royalties and sales-based payments, and it remains central to Poxel’s value proposition. Beyond TWYMEEG®, the company has continued to focus on research programs in rare diseases and metabolic indications, aiming to convert its scientific expertise into future clinical and commercial opportunities. Its business model is therefore characteristic of a clinical-stage biotech: heavy emphasis on R&D, pipeline optionality, partnership monetization, and a relatively limited direct commercial footprint.
Read moreShow less
In market terms, Poxel is a niche specialist rather than a broad-based pharmaceutical player. It operates in a highly competitive and capital-intensive segment, where clinical outcomes, regulatory milestones, and financing conditions can significantly affect corporate value. Recent disclosures indicate that the company has been working through a financial restructuring and recovery plan, underscoring both the funding pressure typical of development-stage biotechs and management’s efforts to preserve operations. Geographically, Poxel’s footprint is international but compact: strategic functions are anchored in France, while Boston and Tokyo support its U.S. and Japanese activities. Notable for its scientific focus and for having brought a first-in-class metabolic asset to market in Japan, Poxel remains a company whose equity story is driven by pipeline execution, partner economics, and the successful conversion of R&D into long-term shareholder value.
